首页 | 本学科首页   官方微博 | 高级检索  
     


nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial
Authors:Rosemary Young  Paul Mainwaring  Philip Clingan  Francis Xavier Parnis  Gholamreza Asghari  Philip Beale  Abdalla Aly  Marc Botteman  Alfredo Romano  Stefano Ferrara  Sandra Margunato‐Debay  Marion Harris
Affiliation:1. Medical Oncology, Royal Hobart Hospital, Hobart, Tasmania, Australia;2. Oncology Unit, Canossa Private Hospital, Oxley, Queensland, Australia;3. Medical Oncology, Southern Medical Day Care Centre, Wollongong, New South Wales, Australia;4. Department of Medical Oncology, Adelaide Cancer Centre (T/A Ashford Cancer Centre), Kurralta Park, South Australia, Australia;5. Bankstown Cancer Centre, Bankstown‐Lidcombe Hospital, Bankstown, New South Wales, Australia;6. Cancer Services and Palliative Care, Sydney Cancer Centre, Concord, New South Wales, Australia;7. Real‐World Evidence and Data Analytics Center of Excellence, Pharmerit International, Bethesda, Maryland, USA;8. Celgene R&D Sarl, Celgene Corporation, Summit, New Jersey, USA;9. Familial Cancer Centre, Monash Health, East Bentleigh, Victoria, Australia
Abstract:
Keywords:albumin‐bound paclitaxel  Australia  combination chemotherapy  gemcitabine  pancreatic cancer
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号